Related Experiment Video
Updated: Mar 31, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
[Advances in Diagnosis and Treatment of Multiple Primary Lung Cancer]
Wenxin Luo1, Ping Zhou1, Weimin Li1
1Department of Respiratory, West-China Hospital of Sichuan University, Chengdu 610041, China.
Abstract:
Recently, the incidence and detection rates of multiple primary lung cancer (MPLC) are increasing. The diagnosis of MPLC depends mainly on the Martini-Melamed criterion and ACCP criterion at present, taking all features (histological, genetic, radiologic and clinical) into account. It may be easy to diagnose cases of MPLC that exhibit different histological types, but it is difficult to diagnose cases that exhibit similar histological type. DNA polity, gene mutations, microsatellite alteration and so on provide new methods for the accurate diagnosis of MPLC. They can evaluate the clonal relationship and help differential diagnosis between MPLC and metastasis. The first therapeutic choice for MPLC is curative operation. The surgical approach includes lobectomy, wedge resection and segmentectomy. For those which cannot be resected, we can synthesize chemotherapy, radiotherapy, stereotactic ablative radiotherapy (SABR), radiofrequency ablation (RFA), molecular targeted therapy, etc.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
05:17Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025